Bladder EpiCheck triggered Photodynamic Diagnosis biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy
2025-12-16
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix to Present Data Showcasing Performance and Clinical Utility of Bladder EpiCheck® Monitoring in Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence at AUA 2025
2025-04-25
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will present...
NHS Lothian and Nucleix Presented Data at EAU25 Showcasing Potential of Bladder EpiCheck® to Improve Detection of Disease Recurrence in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients
2025-03-25
EDINBURGH, Scotland & SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--NHS Lothian, Scotland’s second largest health authority providing a comprehensive range of...
A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in Europe
2024-09-09
FLORENCE, Italy & SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market,...
Results from Pivotal Clinical Study Demonstrate Potential of Nucleix’s Bladder EpiCheck® to Improve Disease Recurrence Detection in Non-Muscle Invasive Bladder Cancer (NMIBC) Surveillance
2024-05-06
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced that...